Bile Duct Function and Disease Highlighted in New Research Study
Recent research from the Gupta Lab, led by Serrena Singh and supervised by Vikas Gupta, MD, PhD, assistant professor of medicine (digestive diseases), provides insights into the extrahepatic bile ducts. These bile ducts outside of the liver are a critical but poorly understood component of the human digestive system. This study, which was published in the journal Development Cell, marks a significant step forward in understanding diseases affecting these ducts, such as primary sclerosing cholangitis and cholangiocarcinoma.
Thalidomide Use In Gastrointestinal Bleeding
Angiodysplasia, a type of benign vascular lesion made up of dilated blood vessels, is a common source of gastrointestinal bleeding from the small intestine. A recent editorial from Yale Internal Medicine’s Loren Laine, MD, professor of medicine and chief of digestive diseases, in the New England Journal of Medicine highlights novel findings from a recent multicenter, double-blind, randomized clinical trial evaluating thalidomide in the treatment of angiodysplasia-related bleeding.
Yale Researchers Develop New Testing Criteria for Hereditary Stomach Cancer
Yale researchers have shown that individuals who carry a mutation in the CDH1 gene have a 30% to 40% risk of developing stomach cancer during their lifetime. Yet many people with the rare inherited condition remain unaware that they have it.
Welcome New Staff, Faculty, Postdoctoral Associates/Fellows & Postgraduate Associates/Fellows (Nov. 2023)
The Department of Internal Medicine is pleased to welcome the following new faculty, staff members, postgraduate associates / fellows, and postgraduate associates / fellows who joined us in October 2023...
Alcohol Research Conference Fosters Collaboration Across Specialties
Now in its second year, the Yale Conference for Alcohol Research and Education (YCARE) was held on September 30, 2023. Offering a comprehensive agenda of talks, panel discussions, and poster presentations, the all-day event brought together Yale's researchers, clinicians, and other stakeholders under the banner of alcohol research. Bubu Banini, MD, PhD, assistant professor of medicine (digestive diseases), Yale School of Medicine (YSM), spearheaded the conference, along with co-directors David Fiellin, MD, professor of medicine (general medicine) and emergency medicine, YSM, and public health, Yale School of Public Health; Graeme Mason, PhD, professor of radiology and biomedical imaging and of psychiatry, YSM; and Sherry McKee, PhD, professor of psychiatry, YSM.
Moeller, Brewster, and Thanas Win the 2023 Rosemarie L. Fisher, MD, Excellence in Graduate Medical Education Award
Two Yale School of Medicine (YSM) faculty and one staff member have won the 2023 Rosemarie L. Fisher, MD, Excellence in Graduate Medical Education (GME) Award: Jeremy Moeller, MD, residency program director for the Neurology program; Ursula Brewster, MD, fellowship program director for the Internal Medicine Nephrology Fellowship Program; and MarySarah Thanas, MPH, program coordinator for the Combined Internal Medicine/Pediatrics Residency Program.
Digestive Diseases Program Facilitates Research for Investigators and Study Coordinators
Investigators in the Yale School of Medicine Section of Digestive Diseases are conducting clinical trials in a variety of areas, including fatty liver disease, hepatitis, inflammatory bowel disease, and primary sclerosing cholangitis. The studies serve to help patients with complicated conditions who either have no treatment options or who would like to try novel therapies.
Yale Program Treats Individuals at High Risk for Gastrointestinal and Pancreatic Cancers
Yale’s Digestive Health Center, a hub offering advanced medical and surgical treatments for individuals with gastrointestinal issues, recently opened the Gastrointestinal (GI) and Pancreatic Cancer Prevention Program at its North Haven location.
The #1 Early Sign of Liver Cancer Most People Miss
There's been some uplifting news about liver cancer in recent years. Statistics show that, after years of increasing cases, global liver cancer rates have decreased significantly in men and women from 2000 to 2016. That's the good news. Unfortunately, about 19,000 men and 9,000 women die from the disease in the U.S. every year, according to the CDC. Understanding your risk and potential red flags can help you take life-saving action early. "Liver disease remains non-symptomatic for a long time," says Dr. Mario Strazzabosco, MD, Ph.D., a clinical program leader and the director of the Liver Cancer Program at Yale Cancer Center and Smilow Cancer Hospital. "Given [that], it is very important to know the risk factors for liver cancer."Source: Parade